The purchase price is a 60% premium over BioForm's closing price on Dec. 31, 2009, of $3.40 a share, and a 55% premium over BioForm Medical's 30-day average closing stock price.
BioForm's main product is the Radiesse dermal filler. Merz is involved in aesthetic medicine.
The transaction is expected to close in the first quarter.-- Reported by Joseph Woelfel in New York. Follow TheStreet.com on Twitter and become a fan on Facebook.